ArticleThe Lancet regional health. Western Pacific2026
Emergence of antimicrobial resistance in New Caledonia: 20-year trends from laboratory-based surveillance (2005-2024).
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antimicrobial resistance (AMR) issues have emerged in New Caledonia, particularly involving methicillin-resistant Methods: A prospective collection of antimicrobial susceptibility testing results was performed over a 20-year period (2005-2024) in the Territorial Hospital Center, the main hospital in New Caledonia. This surveillance encompassed 22 different pathogens and 28 antimicrobial agents, covering 157 pathogen-drug combinations. Resistance rates over time were analyzed using logistic models. A focus was placed on high-priority pathogens, including MRSA, CR-AB, vancomycin-resistant Findings: Across 111,022 included isolates, emergences of resistance were observed, notably to penicillins, third-generation cephalosporins, tetracycline, and fusidic acid. Temporal resistance trends were described, along with outbreaks of MRSA and CR-AB, and the emergence of ESBL-E and CPE, representing 3.7% [95% CI: 3.5-3.8] (N = 2208), and 0.1% [95% CI: 0.1-0.2] (N = 85) of the 59,954 Enterobacterales isolates, respectively. Overall, 11% [95% CI: 10.8-11.1] were MDR and 0.6% [95% CI: 0.5-0.6] were pXDR. Interpretation: Through trend analyses, this surveillance highlighted both the emergence and decline of AMR across diverse bacterial pathogens, helping inform which antibiotics may remain appropriate as first-line options and addressing the lack of data from Pacific Island settings. Funding: This work received financial support from the Pierre Ledoux Jeunesse Internationale scholarship (Fondation de France) and the Institut Pasteur, Paris.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.